Latest News

Oryzon completes funding

Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.
Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.


by Uta Mommert

Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

The financing round has been subscribed by several Spanish commercial banks in the form of long term loans at the current interest rates in the Spanish bank market. “These funds complement the capital increase that the company made upon its listing on the Spanish Market, and are a key component to our strategic Financial Plan,” said Enric Rello, CFO of Oryzon. “These funds will be important to further advance our clinical programmes in Alzheimer’s disease and in other devastating diseases.”

Oryzon Genomics has currently two programmes in clinical stage with different LSD1 inhibitors in cancer and neurodegeneration. Recently, the biopharmaceutical company started a Phase I trial of its oral LSD1-MAOB dual inhibitor ORY-2001. With a successful study outcome, ORY-2001 is expected to proceed to a Phase II study in Alzheimer’s disease patients in early 2017.

© european-biotechnology-news.com/um

Tissue specific tumour transition needs few cells

Anja Voss-Böhme from University Dresden and researchers at the German Cancer Center in Heidelberg used a model that links epigenetic and genetic...

Valneva inks $59m JE vaccine supply contract

Under the agreement, Valneva will supply its FDA-approved preventive vaccine for Japanese encephalitis (JE) from 2019 to 2020. There is a minimum...

Evotec and HZI join forces in antibiotics discovery

Under the collaboration, the partners will initially focus on optimisation of cystobactamids, a family of natural broad-spectrum myvobacterial...

Treating diabetes by mimicking gut bacteria effects

In Nature Chemical Biology, the international team headed by Graeme Milligan from University of Glasgow report that drugs might mimic the...

EMA recommends bluebird's β-thalassemia gene therapy

Patients suffering from beta-thalassaemia cannot produce enough beta-globin, a key component of haemoglobin, the protein that carries the oxygen in...

How salt triggers allergy

German researchers have found that or sodium chloride could be a promotor in allergic responses of the immune system. In Science Translational...

Researchers target neuroblastoma with ALK-ADC

Anaplastic lymphoma kinase (ALK) has been demonstrated to be a moving target expressed in neuroblastomas: if targeted with small-molecule inhibitors,...